Coherus BioSciences

Yahoo Finance • 2 months ago

Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now

We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers.In this article, we are going to take a look at where Coherus BioSciences, Inc. (NASDAQ:CHRS) stands against the other Worst 52-Week Low S... Full story

Yahoo Finance • 2 months ago

Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges

We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Coherus BioSciences, Inc. (NASDAQ:CHRS) stands against the other worst 52-week low sto... Full story

Yahoo Finance • 11 months ago

2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street

growth curve Small-cap stocks have been under pressure ever since the Federal Reserve started hiking interest rates in the first quarter of 2022. As a result, scores of companies in this category sport rock-bottom valuations right now. Wi... Full story

Yahoo Finance • 11 months ago

Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. REDWOOD CITY, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 20, 2023, the compensation committee of the Co... Full story

Yahoo Finance • 11 months ago

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

Coherus BioSciences, Inc. – NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy; LOQTOR... Full story

Yahoo Finance • 12 months ago

Coherus BioSciences Announces CFO Transition Plans

Coherus BioSciences, Inc. REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that McDavid Stilwell, Chief Financial Officer (CFO), has resigned from the company to pu... Full story

Yahoo Finance • 12 months ago

Market Today: Boeing Soars on Upgraded Price Target, GameStop Rallies Ahead of Earnings

Improved confidence in the supply chains ability to support strong demand in the aircraft industry has led to a positive outlook for Boeing (NYSE:BA). RBC Capital Markets analyst Ken Herbert has increased the price target for Boeing to $27... Full story

Yahoo Finance • last year

Coherus BioSciences to Participate at Upcoming November Investor Conferences

REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Truist Securities BioPharma Sympo... Full story

Yahoo Finance • last year

Coherus BioSciences to Participate at Upcoming September Investor Conferences

REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences: Citi's 2023 18th Annual BioPharm... Full story

Yahoo Finance • last year

Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF) (“Surface”), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today anno... Full story

Yahoo Finance • last year

Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M

Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. The Surfac... Full story

Yahoo Finance • 2 years ago

Coherus Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock. In addition... Full story

Yahoo Finance • 2 years ago

Coherus BioSciences to Present at Upcoming Investor Conferences in March

Coherus BioSciences, Inc. REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March. 43... Full story

Yahoo Finance • 2 years ago

Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Coherus BioSciences, Inc. REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after mark... Full story

Yahoo Finance • 2 years ago

Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Ja... Full story

Yahoo Finance • 2 years ago

Should You Invest in Coherus BioSciences (CHRS)?

Scout Investments, an affiliate of Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” third quarter 2022 investor letter. You can download a copy of the same here. The fund underperforme... Full story

Yahoo Finance • 2 years ago

Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022

Coherus BioSciences, Inc. REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after market close on T... Full story

Yahoo Finance • 2 years ago

Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

-FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved - REDWOOD CITY, Calif., and SHANGHAI, China, July 06, 2022 (GL... Full story

Yahoo Finance • 3 years ago

Coherus BioSciences Reports First Quarter 2022 Results

– CIMERLI™ BLA review progressing toward August 2022 action date – – Toripalimab BLA resubmission expected by mid-summer – – UDENYCA® delivers 1st quarter 2022 net sales of $60.1 million – – 2022 R&D and SG&A expense guidance reduced by... Full story

Yahoo Finance • 3 years ago

FDA rejects Peninsula biotech's cancer drug — at least for now

The company, working with its partner in China, plans to ask the FDA in August to approve the drug against a type of head-and-neck cancer.... Full story